RetCAD
With global costs of vision loss estimated to be nearly $3 trillion and up to 80% cases of retinal diseases causing visual impairment or blindness that can often be prevented if detected timely, artificial intelligence opens up a whole new possibilities in eye care. Imaging is non-invasive and reliable screening method but requires expertise to analyse/read the acquired images. Using artificial intelligence, this can be done quickly, yet accurately. RetCAD™ uses state-of-the-art deep learning and computer vision technology utilizing a large amount of retinal images in order to provide precisely quantified clinical evidence. The software assists eye care specialists in early diagnosis and grading of vision threatening diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Simplified visualization of the scan analysis with heat maps help improve patient engagement and prevent severe eyesight problems and blindness.
Valuation
Funding
Ventures > RetCAD
RetCAD
Active
With global costs of vision loss estimated to be nearly $3 trillion and up to 80% cases of retinal diseases causing visual impairment or blindness that can often be prevented if detected timely, artificial intelligence opens up a whole new possibilities in eye care. Imaging is non-invasive and reliable screening method but requires expertise to analyse/read the acquired images. Using artificial intelligence, this can be done quickly, yet accurately. RetCAD™ uses state-of-the-art deep learning and computer vision technology utilizing a large amount of retinal images in order to provide precisely quantified clinical evidence. The software assists eye care specialists in early diagnosis and grading of vision threatening diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Simplified visualization of the scan analysis with heat maps help improve patient engagement and prevent severe eyesight problems and blindness.
- Funding